Clinical Scorecard: Trends in Multiple Sclerosis in Denmark (1950–2023): Analysis of Age, Gender Distribution, Incidence, and Prevalence
At a Glance
Category
Detail
Condition
Multiple Sclerosis (MS), a chronic immune-mediated disease affecting the central nervous system
Key Mechanisms
Immune-mediated CNS damage leading to neurological impairment; demographic shifts influenced by treatment advances and life expectancy
Target Population
Danish individuals diagnosed with MS residing in Denmark from 1950 to 2023
Care Setting
Nationwide MS clinics in Denmark with exclusive authorization to prescribe and dispense disease-modifying therapies
Key Highlights
Mean age of the Danish MS population increased from ~52.5 years in the late 1970s to a peak of 54.2 years in 2023, with minor fluctuations.
Female proportion in the MS population rose from 58.7% in 1975 to 68.5% in 2023, paralleling an increase in prevalence.
MS incidence increased more than threefold from ~3.5 per 100,000 before 1975 to 11.4 per 100,000 by 2000, then stabilized with slight recent decreases.
Guideline-Based Recommendations
Diagnosis
Confirm MS diagnosis through specialized MS clinics authorized in Denmark.
Utilize nationwide registries for accurate epidemiological tracking and diagnosis confirmation.
Management
Implement disease-modifying therapies (DMTs) as standard care since 1996, with mandatory recording of treated patients.
Tailor healthcare strategies considering demographic shifts including aging population and increasing female prevalence.
Monitoring & Follow-up
Regularly update patient registries to monitor age distribution, sex ratio, incidence, and prevalence trends.
Use registry data to assess treatment impact on disease progression and demographic changes.
Risks
Consider increased incidence of late-onset MS influencing demographic and clinical characteristics.
Account for potential sex-related risk factors given the rising female predominance in MS population.
Patient & Prescribing Data
All Danish MS patients receiving care in specialized MS clinics from 1996 onwards.
Since DMT introduction in 1996, mandatory data recording ensures high completeness; treatment advances have postponed functional decline and altered demographic profiles.
Clinical Best Practices
Leverage comprehensive national registries for accurate epidemiological surveillance and research.
Ensure exclusive management of MS patients through authorized MS clinics to maintain data quality and treatment consistency.
Adapt healthcare planning and resource allocation based on evolving demographic trends including aging and sex distribution changes.
